Kufer, Peter,Klinger, Matthias,Hoffmann, Patrick,Naegele, Virginie,Dopfer, Elaine-Pashupati,Nagorsen, Dirk,Scheele, Juergen,Zugmaier, Gerhard
申请号：
AU2014214020
公开号：
AU2014214020B2
申请日:
2014.02.07
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.
